Navigation Links
Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients
Date:4/23/2009

thout anemia (hemoglobin did not decrease to less than 10 g/dL). Anemia is a known adverse event with combination therapy for hepatitis C and this association with higher SVR has been seen in other clinical studies with peginterferon and ribavirin, including the IDEAL study.(4) Boceprevir is associated with about a 1 g/dL incremental decrease in hemoglobin. In the HCV SPRINT-1 study, anemia occurred in approximately half of the patients in the boceprevir arms and over a third of patients in the control arm. Erythropoietin (EPO) supplementation was allowed in the study at the discretion of the investigator and was used by 26 percent of patients in the control arm and 39-51 percent of patients in the boceprevir arms with standard-dose REBETOL.

Safety data from the study showed that the most common adverse events reported in the boceprevir arms were fatigue, anemia, nausea and headache. The incidence of skin adverse events (rash or pruritus) observed in the boceprevir arms was similar to that seen in the PEGINTRON and REBETOL control arm.

Treatment discontinuations due to adverse events in Part I of the study were between 9 and 19 percent for patients in the boceprevir arms, compared to 8 percent for the control arm. Treatment discontinuations for boceprevir patients due to viral breakthrough were fewer in the 28- and 48-week lead-in arms (4 and 5 percent, respectively) compared to the no lead-in arms (7 and 12 percent, respectively).

SCH 900518 (Next-Generation HCV Protease Inhibitor) Data at EASL

Researchers at EASL also presented early phase clinical data for SCH 900518, Schering-Plough's investigational next-generation HCV protease inhibitor.(5) This proof-of-concept study explored the safety and antiviral activity of two different dosing regimens for SCH 900518 administered as monotherapy and in combination therapy with PEGINTRON with or without ritonavir in treatment-naive and treatmen
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
2. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
3. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
4. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
5. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
6. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
7. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
8. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
9. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
10. The Anatomy of Clinical Trials: Greys Season Finale Leaves Public in the Dark About the Myths and Realities
11. Final Results of the CellCept(R) Spare the Nephron (STN) Study Show Maintenance Therapy is Associated with Improved Renal Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... YORK, Dec. 17 Reportlinker.com ... report is available in its catalogue: ... (NPWT) Pipeline Technology and Market Forecasts ... ,, Negative Pressure Wound ... Forecasts to 2016 ,, Summary ...
(Date:12/17/2009)... ,Agendia, a world leader in molecular cancer ... Administration (FDA) cleared its MammaPrint breast,cancer recurrence test ... cancer recurrence test available to patients and physicians. ... four clearances for MammaPrint, covering,all aspects of this ... FDA clearance, along with our recently obtained CMS ...
(Date:12/17/2009)... LOS ANGELES, Dec. 17 Instacare Corp. ... of life-saving and life-enhancing prescription drugs and diagnostics ... ill, and a leading developer and provider of ... and products announced today that as part of ... Board has determined to add two new Directors ...
Breaking Medicine Technology:Reportlinker Adds Negative Pressure Wound Therapy (NPWT) Pipeline Technology and Market Forecasts to 2016 2Reportlinker Adds Negative Pressure Wound Therapy (NPWT) Pipeline Technology and Market Forecasts to 2016 3Reportlinker Adds Negative Pressure Wound Therapy (NPWT) Pipeline Technology and Market Forecasts to 2016 4Reportlinker Adds Negative Pressure Wound Therapy (NPWT) Pipeline Technology and Market Forecasts to 2016 5Reportlinker Adds Negative Pressure Wound Therapy (NPWT) Pipeline Technology and Market Forecasts to 2016 6FDA Broadens Clearance for Agendia's MammaPrint(R) 2Instacare Corp. Board of Directors Sets Growth Plans for 2010 2SOWSIAs Inpatient EHR Solution Gets 08 CCHIT Certification 52400 1SOWSIAs Inpatient EHR Solution Gets 08 CCHIT Certification 52400 2SOWSIAs Inpatient EHR Solution Gets 08 CCHIT Certification 52400 3Investigational Urine NGAL Biomarker Shows Promise to Monitor Cyclosporine Toxicity in Cardiac Transplant Patients 13147 1Investigational Urine NGAL Biomarker Shows Promise to Monitor Cyclosporine Toxicity in Cardiac Transplant Patients 13147 2Fecal incontinence and quality of life 52393 1
... Excellent results obtained with a newly cleared device to identify ... are associated with ... complications of coronary stenting, BURLINGTON, Mass., May 15 ... Royal Oak, Mich., have,successfully used its LipiScan(TM) Coronary Imaging System ...
... Switzerland, May 15 Ergonex Pharma today,announced that ... has,granted orphan drug designation to Terguride for the ... being evaluated for PAH,in a pivotal Phase II ... orphan drug designation to Terguride for PAH,encourages and ...
Other Medicine Technology:First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 2First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 3First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 4Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension 2
(Date:12/17/2009)... good time to get vaccinated, federal officials urge , ... current wave of H1N1 swine flu continues to wane, ... vaccinated in case another outbreak strikes this winter. , ... have eased, it,s an ideal time to get vaccinated, ... said during a morning press conference. , "Our message ...
(Date:12/17/2009)... pain is now available in Rockville and Gaithersburg, Maryland. This ... sometimes even fall asleep during their treatment. , ... ... Maryland can now rejoice as The Spinal Correction & Wellness Center ... discs., , ,Humans are constantly under pressure from gravitational forces which ...
(Date:12/17/2009)... Reportlinker.com announces that a ... in its catalogue: ,, http://www.reportlinker.com/p0169972/Top-Ten-Worlds-Leading-Life-Science-Intermediates-Companies.html ... the competitive environment is widely recognized ... management responsibilities, the task crucial to ... and factual competitive intelligence is vital ...
(Date:12/17/2009)... following feature is by Devon Herrick, PhD, Senior Fellow ... People often assume they have little control over how ... sickness cannot be scheduled, doctors prescribe treatments and employers ... Americans. However, there are many overlooked ways to trim ... need. ,, Cut your prescription costs: ...
(Date:12/17/2009)... China,s leading high-tech,healthcare group, Golden Meditech Company Limited ... pleased to announce today the interim results for,Financial ... Group,s two,associate companies made their debut on the ... have been strengthened, with maiden revenue and profit,contributions ... Mr. KAM Yuen, Chairman and ...
Breaking Medicine News(10 mins):Health News:Swine Flu Wanes, But Future Uncertain 2Health News:Rockville and Gaithersburg Now Has Spinal Decompression Therapy 2Health News:Rockville and Gaithersburg Now Has Spinal Decompression Therapy 3Health News:Reportlinker Adds Top Ten World's Leading Life Science Intermediates Companies 2Health News:Six Ways to Slash Your Health Costs 2Health News:Six Ways to Slash Your Health Costs 3Health News:Six Ways to Slash Your Health Costs 4Health News:Golden Meditech Announces Interim Results of FY2009/10 2Health News:Golden Meditech Announces Interim Results of FY2009/10 3
... The Alliance for Lupus Research hosts 3rd Advocacy ... March 4th,advocates for the Alliance for Lupus Research ... lupus, described their personal experiences with the,disease to ... 100,Congressional offices, representing 21 states, and asked their ...
... Quality,Improvements, * 4 p.m., Monday, March 10: ... Battery St., San Francisco, SAN FRANCISCO, March ... chain,s attempts to weaken its,employees and their union, ... is scheduled to begin., Within the next ...
... doctors twice as likely to recommend replacement surgery for men ... with knee pain are less likely than men to be ... that suggests gender bias may be a factor. , The ... with moderate knee osteoarthritis (OA) who reported the same pain ...
... 10 Tired of,frequent Botox injection visits? GFX ... Newly-FDA approved GFX (Glabella Furrow Relaxation) recently arrived ... radiofrequency waves, to be,exact -- in select aesthetic ... technological advancement in facial rejuvenation that offers,long-term relaxation ...
... (WDS) is pleased to announce the 2008-2009 presidency of ... WDS luncheon during the,American Academy of Dermatology Annual Meeting ... role from this past year,s position as,WDS Vice-President and ... Lupo, MD, served as the WDS 2007-08 President., ...
... the hands of jewelers, gold can be fashioned into ... in size to nanocrystals containing a few thousand atoms, ... the key to golds chemical reactivity (or that of ... techniques work at the nanoscale. Now, researchers at the ...
Other Medicine News:Health News:Working Together for a Cure 2Health News:Working Together for a Cure 3Health News:UHW to SEIU, Nursing Home Chain: Stop Undermining Workers 2Health News:Gender Bias at Play in Treatment of Knee Osteoarthritis 2Health News:GFX: Wrinkle-Killer or Botox(R) Hit-Man? 2Health News:GFX: Wrinkle-Killer or Botox(R) Hit-Man? 3Health News:Suzanne M. Connolly, MD Named 2008-2009 President of Women's Dermatologic Society 2Health News:Measurement technique probes surface structure of gold nanocrystals 2
... accurate lesion assessment plays a ... the appropriate stent size and ... (IC3D), a highly precise three-dimensional ... now able to quickly quantify ...
... dTC is a versatile solution designed to ... from preparation to diagnosis and therapy, ... AXIOM Artis dTC, your cath lab becomes ... that leaves you free to concentrate on ...
... AXIOM Artis FC is a ... with flexible system architecture for ... interventions. The flexible and ergonomic ... optimally adapt the system configuration ...
The ACUSON Sequoia C512 system elevates imaging and Doppler performance through new, high-density acoustic sampling, precise control of the transmitted acoustic waveform, and new transducer technolog...
Medicine Products: